ShoreCap hails 'promising' results of Valneva's Scottish Covid-19 vaccine
By Alexander Bueso
Date: Tuesday 06 Apr 2021
(Sharecast News) - Analysts at Shore Capital hailed the "promising" results of French vaccine manufacturer Valneva's early-stage clinical trials for its proposed shot against Covid-19.
According to Valneva, the first part of its Phase 1/2 clinical trial for its vaccine candidate, known as VLA2001, all volunteers in a group of patients given a high dose of the shot developed antibodies, as did approximately 90% of those in the low dose group.
The trials' results also showed that the level of neutralising antibodies created was at or above that in people who had recovered from the virus naturally.
"This is important as this metric has been predictive of success in other vaccine trials," they said.
ShoreCap also noted the fact that Valneva's was the first vaccine based on the "whole", but inactivated virus.
That might make it more resistante to new virus strains.
Furthermore, the UK already 60.0m doses of the vaccine - which was to be manufactured in Scotland - on order for the first quarter of 2022.
The vaccine raised no serious safety concerns during the trials, which also showed broad T-cell responses against multiple virus proteins, including the so-called 'spike' protein.
Those responses did however vary according to the different proteins, they said.
"Despite the potential issue of a weak immune response (which doesn't appear to be the case from the initial data), the big promise of whole, inactivated viruses is that they include the whole virus itself and hence all of its proteins," ShoreCap's Drs. Adam Barker and Tara Raveendran said.
"As such, you would expect the immune response to be broader and arguably more robust i.e. it could be more protective against novel variants (a single virus variant will find it hard to mutate away from an immune response which targets multiple parts of it)."
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN